A Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer
A phase II study to evaluate the safety and efficacy of oral sapacitabine in previously treated advanced non-small cell lung cancer (NSCLC).
Non-small Cell Lung Cancer
DRUG: sapacitabine
the rate of response and stable disease, complete response or partial response and stable disease, after cycle 2, 4, 7 and every 3 cycles thereafter
progression-free survival, Time until disease progression, 1.5 years|duration of response, Observed response time, 1.5 years|duration of stable disease, Observed time of the disease state within -30% and +10% of the baseline, 1.5 years|overall survival, Median survival time of the overall patient population in the study, 1.5 years
This is an open label, single arm, phase II study to evaluate the safety and efficacy of oral sapacitabine administered twice daily for 5 consecutive days every week for 2 weeks followed by 7-day rest in patients who have had one prior chemotherapy regimen for advanced Non-Small Cell Lung Cancer (NSCLC).